Palvella Therapeutics, Inc (NASDAQ:PVLA) — Market Cap & Net Worth
Market Cap & Net Worth: Palvella Therapeutics, Inc (PVLA)
Palvella Therapeutics, Inc (NASDAQ:PVLA) has a market capitalization of $2.18 Billion ($2.18 Billion) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #5873 globally and #1908 in its home market, demonstrating a -0.56% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Palvella Therapeutics, Inc's stock price $151.43 by its total outstanding shares 14408407 (14.41 Million). Also see PVLA total asset value for a full breakdown of the balance sheet.
Palvella Therapeutics, Inc Market Cap History: 2024 to 2026
Palvella Therapeutics, Inc's market capitalization history from 2024 to 2026. Data shows growth from $172.90 Million to $2.18 Billion (307.39% CAGR). Also see how efficiently does Palvella Therapeutics, Inc generate cash for how efficiently the company converts equity into cash flow.
Index Memberships
Palvella Therapeutics, Inc is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.08% | #161 of 976 |
Weight: Palvella Therapeutics, Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Palvella Therapeutics, Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Palvella Therapeutics, Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Palvella Therapeutics, Inc (PVLA) stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PVLA by Market Capitalization
Companies near Palvella Therapeutics, Inc in the global market cap rankings as of September 18, 2026. Review tangible net worth ratio of Palvella Therapeutics, Inc to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Palvella Therapeutics, Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Palvella Therapeutics, Inc Historical Marketcap From 2024 to 2026
Between 2024 and today, Palvella Therapeutics, Inc's market cap moved from $172.90 Million to $ 2.18 Billion, with a yearly change of 307.39%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.18 Billion | +44.67% |
| 2025 | $1.51 Billion | +772.25% |
| 2024 | $172.90 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Palvella Therapeutics, Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.18 Billion USD |
| MoneyControl | $2.18 Billion USD |
| MarketWatch | $2.18 Billion USD |
| marketcap.company | $2.18 Billion USD |
| Reuters | $2.18 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Palvella Therapeutics, Inc
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 cl… Read more